Sign Up Today and Learn More About Vedanta Biosciences Stock

Invest in or calculate the value of your shares in Vedanta Biosciences or other pre-IPO companies through EquityZen's platform.

Get Started

Vedanta Biosciences Stock

Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.

About Vedanta Biosciences Stock

Founded

2010

Headquarters

Cambridge, MA, US

Total Funding

55.4M

Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.

Vedanta Biosciences Press Mentions

Stay in the know about the latest news on Vedanta Biosciences

Vedanta Biosciences Management

Leadership team at Vedanta Biosciences

Scientific Co-Founder

Dan Littman

Scientific Co-Founder

Alexander Rudensky

Locked Features

Join now and verify your accreditation status to gain access to:

  • Vedanta Biosciences current valuation
  • Vedanta Biosciences stock price
  • Available deals in Vedanta Biosciences and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Vedanta Biosciences stock?

Accredited investors can buy pre-IPO stock in companies like Vedanta Biosciences through EquityZen funds. These investments are made available by existing Vedanta Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Vedanta Biosciences stock?

Shareholders can sell their Vedanta Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."